The price-to-earnings ratio for Neurocrine Biosciences, Inc (NASDAQ: NBIX) is 33.03x, which is above its average ratio. Moreover, the 36-month beta value for NBIX is 0.33. Analysts have varying opinions on the stock, with 15 analysts rating it as a “buy,” 8 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for NBIX is 98.56M and currently, short sellers hold a 2.52% of that float. On November 21, 2024, NBIX’s average trading volume was 990.71K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NBIX) stock’s latest price update
Neurocrine Biosciences, Inc (NASDAQ: NBIX) has seen a rise in its stock price by 3.49 in relation to its previous close of 119.13. However, the company has experienced a -1.77% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-08 that Neurocrine Biosciences, Inc.’s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slow growth big pharma multiples, not at multiples of a company with significant growth potential that it is. Ingrezza continues to deliver strong growth and cash flows for the company, and crinecerfont will be launched in early 2025.
NBIX’s Market Performance
NBIX’s stock has fallen by -1.77% in the past week, with a monthly rise of 5.57% and a quarterly drop of -19.19%. The volatility ratio for the week is 3.43% while the volatility levels for the last 30 days are 2.76% for Neurocrine Biosciences, Inc The simple moving average for the last 20 days is 1.56% for NBIX stock, with a simple moving average of -7.62% for the last 200 days.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Raymond James repeating the rating for NBIX by listing it as a “Outperform.” The predicted price for NBIX in the upcoming period, according to Raymond James is $155 based on the research report published on October 10, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $159, previously predicting the price at $131. The rating they have provided for NBIX stocks is “Overweight” according to the report published on August 29th, 2024.
Wells Fargo gave a rating of “Overweight” to NBIX, setting the target price at $170 in the report published on April 24th of the current year.
NBIX Trading at 4.06% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.96% of loss for the given period.
Volatility was left at 2.76%, however, over the last 30 days, the volatility rate increased by 3.43%, as shares surge +7.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.50% upper at present.
During the last 5 trading sessions, NBIX fell by -1.77%, which changed the moving average for the period of 200-days by -13.76% in comparison to the 20-day moving average, which settled at $121.40. In addition, Neurocrine Biosciences, Inc saw -6.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from Boyer David W., who sale 3,461 shares at the price of $121.88 back on Sep 13 ’24. After this action, Boyer David W. now owns 1,672 shares of Neurocrine Biosciences, Inc, valued at $421,828 using the latest closing price.
DAVID WARREN BOYER, the Officer of Neurocrine Biosciences, Inc, proposed sale 4,756 shares at $121.28 during a trade that took place back on Sep 13 ’24, which means that DAVID WARREN BOYER is holding shares at $576,808 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc stands at 0.17. The total capital return value is set at 0.19. Equity return is now at value 16.35, with 12.09 for asset returns.
Currently, EBITDA for the company is 416.1 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of 5.52. The receivables turnover for the company is 4.66for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.37.
Conclusion
To wrap up, the performance of Neurocrine Biosciences, Inc (NBIX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
